Lipid nanocarriers: Influence of lipids on product development and pharmacokinetics

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 28, Issue 4, 2011, Pages 357-393

  Pathak, Kamla ^a   Keshri, Lav ^a   Shah, Mayank ^a  

^a Rajiv Academy for Pharmacy ^*  (India)

Author keywords

LDC; Lipid drug conjugates; Nanostructured lipid carriers; NLC; Pharmaco somes; Pharmacokinetics; Product development; SLN; Solid lipid nanoparticles

Indexed keywords

ACYLGLYCEROL; AMPHOTERICIN B; BUSPIRONE; CELECOXIB; CISPLATIN; CRYPTOTANSHINONE; CYCLOSPORIN A; DICLOFENAC; DOCETAXEL; GATIFLOXACIN; GLYCEROL STEARATE; IBUPROFEN; KETOPROFEN; LIPID; LOPINAVIR; METHOTREXATE; NANOCARRIER; ORIDONIN; PACLITAXEL; PENTOXIFYLLINE; PHYTOMENADIONE; SIMVASTATIN; SOLID LIPID NANOPARTICLE; STEROID; TAMOXIFEN; TIMOLOL; TRIACYLGLYCEROL; UNINDEXED DRUG; WAX; ZIDOVUDINE;

ARTICLE; BIOAVAILABILITY; BODY TEMPERATURE; CONJUGATE; COVALENT BOND; CRYSTALLIZATION; CYTOTOXICITY; EMULSION; HUMAN; HYDROPHOBICITY; INTESTINE EPITHELIUM CELL; MELTING POINT; NONHUMAN; PARTICLE SIZE; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PRODUCT DEVELOPMENT; SOLUBILIZATION; TRANSMISSION ELECTRON MICROSCOPY; VISCOSITY;

EID: 79961184109     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v28.i4.20     Document Type: Article

References (194)

1. Mader K, Mehnert W. Solid lipid nanoparticles-concepts, procedures and physicochemical aspects. In: Nastruzzi C, editor. Liposphere in drug targets and delivery: approaches, methods and applications. New York: CRC Press; 2005. p. 1-22.
2. Jain S, Jain S, Khare P, Gulbake A, Bansal D, Jain SK. Design and development of solid lipid nanopar-ticles for topical delivery of an anti-fungal agent. Drug Deliv. 2010;17(6):443-51.
3. Vyas SP, Khar RK. Targeted and controlled drug delivery novel carrier systems. 2nd ed. New Delhi, India: CBS Publishers and Distributors; 2002. p. 15-348.
4. Muller RH, Runge S, Ravelli V, Mehnert W, Thunemann AF, Souto EB. Oral bioavailability of cyclosporine: solid lipid nanoparticles versus drug nanocrystals. Int J Pharm. 2006;317:82-9.
5. Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. Solid lipid nanoparticles (SLN) as ocular delivey of tobramycin. Int J Pharm. 2002;238:241-5.
6. Wissing SA, Kayserb O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56:1257-72.
7. Puglia C, Blasi P, Rizza L, Schoubben A, Bonina F, Rossi C, Ricci M. Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int J Pharm. 2008;357:295-304.
8. Esposito E, Fantin M, Marti M, Drechsler M, Paccamiccio L, Mariani P, Sivieri E, Lain F, Menegatti E, Morari M, Cortesi R. Solid lipid nanoparticles as drug delivery for bromocriptine. Pharm Res. 2008;25(7):1521-30.
9. Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery II. Drug incorporation and physicochemical characterization. J Microencapsul. 1999;16(2):205-13.
10. Radtke M, Souto EB, Muller RH. Nanostructured lipid carriers: a novel generation of solid lipid drug carriers. Pharm Tech Eur. 2005;17(4):45-50.
11. Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carrier (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54:S133-51.
12. Wissing SA, Saupe A, Muller RH. Nanostrctured lipid carriers (NLC) for topical use: an overview. Euro Cosmetics. 2003;5:14-7.
13. Olbrich C, Gebner A, Kayser O, Muller RH. Lipid-drug conjugate (LDC) nanoparticles as a novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J Drug Target. 2002;10:387-96.
14. Bera S, Zhanel GG, Schweizer F. Design, synthesis, and antibacterial activities of neomycin-lipid conjugates: polycationic lipids with potent gram-positive activity. J Med Chem. 2008;51(19):6160-4.
15. Semalty A, Semalty M, Rawat BS, Singh D, Rawat MSM. Pharmacosomes: the lipid- based new drug delivery system. Expert Opin Drug Deliv. 2009;6(6):599-612.
16. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery: a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161-77.
17. Westesen K, Siekmann B, Koch MHJ. Investigation on the physical state of lipid nanoparticles by synchrotron X-ray diffraction. Int J Pharm. 1993;93:189-99.
18. Bunjes H, Westesen K, Koch MHJ. Crystallization tendency and polymorphic transitions in triglyce-ride nanoparticles. Int J Pharm. 1996;129;159-73.
19. Hagemann JW. Thermal behaviour and polymorphism of acylglycerides. In: Garti N, Sato K., editors, Crystallization and Polymorphism of Fats and Fatty Acids, Marcel Dekker, New York; 1998. p. 9-95.
20. Hernqvist L. Crystal structures of fats and fatty acids. In: N. Garti N, Sato K. editors., Crystallization and Polymorphism of Fats and Fatty Acids, Marcel Dekker, New York; 1998. p. 97-138.
21. ®): drug-lipid physicochemical interactions and characterization of drug incorporation. Eur J Pharm Biopharm. 2008;68(3):535-44.
22. Kumar VV, Chandrashekhar D, Ramakrishnan S, Kishan V, Rao YM, Diwan PV. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: infuence of wax and glyceride lipids on plasma pharmacokinetics. Int J Pharm. 2007;335:167-75.
23. Castro GA, Coelho ALLR, Oliveira CA, Mahecha GAB, Orefce RL, Ferreira LAM. Formation of ion pairing as an alternative to improve encapsulation and stability and to reduce skin irritation of retinoic acid loaded in solid lipid nanoparticles. Int J Pharm. 2009;381:77-83.
24. Suresh G, Manjunath K, Venkateswarlu V, Satyanarayana V. Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles, AAPS PharmSciTech. 2007;8(1):E1-9.
25. Chen H, Chang X, Du D, Liu W, Liu J, Weng T, Yang Y, Xu H, Yang X. Podophyllotoxin loaded solid lipid nanoparticles for epidermal targeting. J Control Release. 2006;110:296-306.
26. Freitas C, Muller RH. Correlation between long term stability of solid lipid nanoparticles and crystal-linity of lipid phase. Eur J Pharm Biopharm. 1999;47:125-32.
27. Mei Z, Lia X, Wua Q, Hua S, Yang X. The research on the anti infammatory activity and hepatotoxi-city of triptolide-loaded solid lipid nanoparticle. Pharmacol Res. 2005;51:345-51.
28. Doijad RC, Manvi FV, Godhwani DM, Joseph R, Deshmukh NV. Formulation and targeting effciency of cisplatin engineered solid lipid nanoparticles. Indian J Pharm Sci. 2008;70(2):203-7.
29. Zimmermann E, Muller RH. Electrolyte- and pH- stabilities of aqueous solid lipid nanoparticle dispersions in artifcial gastrointestinal media. Eur J Pharm Biopharm. 2001;52:203-10.
30. Pozo-Rodriguez A, Pujals S, Delgado D, Solinis MA, Gascon AR, Giralt E, Pedraz JL. A proline-rich peptide improves cell transfection of solid lipid nanoparticle-based non-viral vectors. J Control Release. 2009;133:52-9.
31. Reddy LH, Murthy RSR. Etoposide-loaded nanoparticles made from glyceride lipids: formulation, characterization, in vitro drug release, and stability evaluation. AAPS Pharm Sci Tech. 2005;6(2):E158-E166.
32. Shah M, Chuttani K, Mishra AK, Pathak K. Oral solid compritol 888 ATO nanosuspension of simvas-tatin: optimization and biodistribution studies. Drug Dev Indust Pharm. 2011;37(5):526-37.
33. Jenning G, Gohla S. Comparison of wax and glyceride solid lipid nanoparticles (SLN). Int J Pharm. 2000;196:219-22.
34. Shah M. Development, optimization and in vivo evaluation of solid lipid nanoparticles of simvastatin. Uttar Pradesh Techl University; 2009.
35. Chawla V, Saraf SA. Glyceryl behenate and its suitability for production of aceclofenac solid lipid nanoparticles. J Am Oil Chem Soc. 2011;88:119-26.
36. Battaglia L, Gallarate M, Cavalli R, Trotta M. Solid lipid nanoparticles produced through a coacerva-tion method. J Microencapsul. 2010;27(1):78-85.
37. Lv Q, Yu A, Xi Y, Li H, Song Z, Cui J, Cao F, Zhai G. Development and evaluation of penciclovir loaded solid lipid nanoparticles for topical delivery. Int J Pharm. 2009;372:191-8.
38. 3 full factorial design. AAPS PharmSciTech. 2010; 11(2):489-96.
39. Tiyaboonchai W, Tungpradit W, Plianbangchang P. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int J Pharm. 2007;337:299-306.
40. Abdelbary G, Fahmy RH. Daizepam loaded solid lipid nanoparticles: design and characterization. AAPS PharmSciTech. 2009:10(1):211-9.
41. Varshosaz J, Ghaffari S, Khoshayand MR, Atyabi F, Azarmi S, Kobarfard F. Development and optimization of solid lipid nanoparticles of amikacin by central composite design. J Liposome Res. 2010;20(2):97-104.
42. Olbrich C, Gessner A, Schroder W, Kayser O, Muller RH. Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene-cytotoxicity testing and mouse serum adsorption. J Control Release. 2004;96:425-35.
43. Jensen LB, Magnussson E, Gunnarsson L, Vermeheren C, Neilson HM, Petersson K. Corticoid solubility and lipid polarity control release from solid lipid nanoparticles. Int J Pharm. 2010;390:3-60.
44. Chen CC, Tsai T, Huang Z, Fang J. Effects of lipophilic emulsifers on the oral administration of lovas-tatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm. 2010;74:474-82.
45. Bhaskar K, Anbu J, Ravichandiran V, Venkateshwarlu V, Rao YM. Lipid nanoparticles for transder-mal delivery of furbiprofen: formulation, in vitro, ex vivo and in vivo studies. Lipids Health Dis. 2009;8(6):1-15.
46. Tiwari R. Formulation, optimization, pharmacokinetics and biodistribution of nanostructured lipid carriers designed for oral lymphatic uptake of simvastatin. Uttar Pradesh Technical University; 2010.
47. Zhang WL, Gu X, Bai H, Yang RH, Dong CD, Liu JP. Nanostructured lipid carriers constituted from high-density lipoprotein components for delivery of a lipophilic cardiovascular drug. Int J Pharm. 2010;391(1-2):313-21.
48. Kim J, Park J, Kim C. Development of a binary lipid nanoparticles formulation of itraconazole for parenteral administration and controlled release. Int J Pharm. 2010;383:209-15.
49. Reddy LH, Sharma RK, Chuttani K, Mishra AK, Murthy RR. Etoposide-incorporated tripalmitin nano-particles with different surface charge: formulation, characterization, radiolabelling and biodistribu-tion studies. AAPS J. 2004;6(3):1-10.
50. nd, Rathman JF. Optimization of β-carotene loaded solid lipid nanoparticles preparation using a high shear homogenization technique. J Nanopart Res. 2009;11:601-14.
51. Fillery-Travis AJ, Foster LH, Robins MM. Stability of emulsions stabilised by two physiological surfactants: l-α-phosphatidylcholine and sodium taurocholate. Biophys Chem. 1995;54:253-60.
52. Leroux J, All'emanna E, Doelker E, Gurny R. New approach for the preparation of nanoparticles by an emulsifcation-diffusion method. Eur J Pharm Biopharm. 1994;41:14-8.
53. Muller-Goymann CC, Schubert MA. Solvent injection as a new approach for manufacturing lipid nano-particles: evaluation of the method and process parameter. Eur J Pharm Biopharm. 2003;55:125-31.
54. Quintanar-Guerrero D, Tamayo-Esquivel D, Ganem-Quintanar A, All'emanna E, Doelker E. Adaptation and optimization of the emulsifcation-diffusion technique to prepare lipidic nanospheres. Eur J Pharm Sci. 2005;26:211-8.
55. Zhang S, Yun J, Shen S, Chen Z, Yao K, Chen J, Chen B. Formation of solid lipid nanoparticles in a microchannel system with a cross shaped junction. Chem Eng Sci. 2008;63:5600-5.
56. D'oria C, Charcosset C, Barresi AA, Fessi H. Preparation of solid lipid particles by membrane emulsi-fcation: infuence of process parameters. Colloids Surf A. 2009;338(1-3):114-8.
57. Trotta M, Debernardi F, Caputo O. Preparation of solid lipid nanoparticles by a solvent emulsifcation-diffusion technique. Int J Pharm. 2003;257:153-60.
58. Li Z, Lin X, Yu L, Li X, Geng F, Zheng L. Effects of chloramphenicol on the characterization of solid lipid nanoparticles and nanostructured lipid carrier. J Dispersion Sci Technol. 2009;30(7):1008-14.
59. Olbrich C, Kayser O, Muller RH. Lipase degradation of Dysnan 114 and 116 solid lipid nanoparticles (SLN): effects of surfactant, storage time and crystallinity. Int J Pharm. 2002;237:119-28.
60. Attama AA, Muller-Goymann CC. Effect of beeswax modifcation on the lipid matrix and solid lipid nanoparticle crystallinity. Colloids Surf A. 2008;315(1-3):189-95.
61. Bernal JL, Jimenez JJ, del Nozal MJ, Toribio L, Martin MT. Physico-chemical parameters for the characterization of pure beeswax and detection of adulterations. Euro J Lipid Sci Technol. 2005;107: 158-66.
62. Kameda T. Molecular structure of crude beeswax studied by solid-state 13C NMR. J. Insect Sci. 2004;4:1.
63. Luzzati V. X-ray diffraction of lipid-water systems, In: Chapman D., editor, Biological Membranes Physical Facts and Function, Academic Press, London, 1968, p. 71-123.
64. Westesen K, Siekmann B. Investigation of the gel formation of phospholipid-stabilized solid lipid nanoparticles. Int J Pharm. 1997;151:35-45.
65. Lukowski G, Kasbohm J, Pfegel P, Illing A, Wulf H. Crystallographic investigation of cetyl palmitate solid lipid nanoparticles. Int J Pharm. 2000;196:201-5.
66. Seetapan N, Bejrapha P, Srinuanchai W, Ruktanonchai UR. Rheological and morphological characterizations on physical stability of gamma-oryzanol-loaded solid lipid nanoparticles (SLNs). Micron. 2010;41(1):51-8.
67. Seetapan N, Bejrapha P, Srinuanchai W, Puttipipatkhachorn S, Ruktanonchai U. Nondestructive rheo-logical measurement of aqueous dispersions of solid lipid nanoparticles: effects of lipid types and concentrations on dispersion consistency. Drug Dev Ind Pharm. 2010;36(9):1005-15.
68. Helgason T, Awad TS, Kristbergsson K, McClements DJ, Weiss J. Infuence of polymorphic transformations on gelation of tripalmitin solid lipid nanoparticle suspensions. J Am Oil Chem Soc. 2008;85(6):501-11.
69. Jores K, Mehnert W, Drechsler M, Bunjes H, Johann C, Mader K. Investigation on the structure of solid lipid nanoparticles (SLN) and oil loaded solid lipid nanoparticles by photon correlation spectroscopy, feld-fow fractionation and transmission electron microscopy. J Control Release. 2004;95(2):217-27.
70. Saupe A, Gordon KC, Rhades T. Structural investigations on nanoemulsions, solid lipid nanoparticles, nanostructured lipid carrier by cryo-feld emission scanning electron microscopy and Raman spectros-copy. Int J Pharm. 2006;314:56-62.
71. Olbrich C, Muller RH. Enzymatic degradation of SLN-effect of surfactant and surfactant mixtures. Int J Pharm. 1999;180:31-9.
72. Li XW, Lin XH, Zheng LQ, Yu L, Mao Z. Preparation, characterization, and in vitro release of chlora-mphenicol loaded solid lipid nanoparticles. J Dispersion Sci Technol. 2008;29(9):1214-21.
73. Shenoy VS, Rajyaguru TH, Gude RP, Murthy RSR. Studies on paclitaxel-loaded glyceryl monostea-rate nanoparticles. J Microencapsul. 2009;26(6):471-8.
74. Shenoy VS, Gude RP, Murthy RSR. Paclitaxel-loaded glyceryl palmitostearate nanoparticles: in vitro release and cytotoxic activity. J Drug Target. 2009;17(4):304-10.
75. Varia JK, Dodiya SS, Sawant KK. Cyclosporine A loaded solid lipid nanoparticles: optimization of formulation, process variable and characterization. Curr Drug Deliv. 2008;5(1):64-9.
76. Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQY, Zeng S. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf B. 2005;45:167-73.
77. Zhang X, Liu J, Qiao H, Liu H, Ni J, Zhang W, Shi Y. Formulation optimization of dihydroarte-misinin nanostructured lipid carrier using response surface methodology. Powder Technol. 2010; 197(1-2):120-8.
78. Yuan H, Chan J, Du YZ, Hu FQ, Zeng S, Zhao HL. Studies on oral absorption of the stearic acid SLN by a novel fuorometric method. Colloids Surf B. 2007;58:157-64.
79. Li H, Zhao X, Ma Y, Zhai G, Li L, Lou H. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release. 2009;133:238-44.
80. Liu D, Liu C, Zou W, Zhang N. Enhanced gastrointestinal aborption of N3O toluyl fuorouracil by cationic solid lipid nanoparticle. J Nanopart Res. 2010;12:975-84.
81. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of cloza-pine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release. 2005;107:215-28.
82. Yang S, Zhu J, Lu Y, Liang B, Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res. 1999;16(5):751-7.
83. Du B, Yan Y, Li Y, Wang S, Zhang Z. Preparation and passive target of 5-fuorouracil solid lipid nano-particles. Pharm Dev Technol. 2010;15(4):346-53.
84. Luo DF, Ye JT, Zhang YS, Liu DY. Studies on drug release in vitro and absorption in rat in vivo of ginsenoside Rd solid lipid nanoparticles. Chin Pharmacol Bull. 2009;25(7):923-6.
85. Kheradmandnia, S., Vasheghani-Farahani, E., Nosrati, M., Atyabi, F. Preparation and characterization of ketoprofen-loaded solid lipid nanoparticles made from beeswax and carnauba wax. Nanomed Nanotechnol Biol Med. 2010;6(6):753-9.
86. Varshosaz J, Tabbakhian M, Mohammadi MY. Formulation and optimization of solid lipid nano-particles of buspirone HCl for enhancement of its oral bioavailability. J Liposome Res. 2010;20(4): 286-96.
87. Alex MRA, Chacko AJ, Jose S, Souto EB. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci. 2011;42(1-2):11-8.
88. Abbasalipourkabir R, Salehzadeh A, Abdullah R. Antitumor activity of tamoxifen loaded solid lipid nanoparticles on induced mammary tumor gland in sprague-dawley rats. Afr J Biotechnol. 2010;9(43):7337-45.
89. Mulik RS, Monkkonen J, Juvonen RO, Mahadik KR, Paradkar AR. Transferrin mediated solid lipid nanoparticles containing curcumin: enhanced in vitro anticancer activity by induction of apoptosis. Int J Pharm. 2010;398(1-2):190-203.
90. Gallarate M, Trotta M, Battaglia L, Chirio D. Cisplatin-loaded SLN produced by coacervation technique. J Drug Deliv Sci Technol. 2010;20(5):343-47.
91. Wei W, Shi SJ, Liu J, Sun X, Ren K, Zhao D, Zhang XN, Zhang ZR, Gong T. Lipid nanoparticles loaded with 10-hydroxycamptothecinphospholipid complex developed for the treatment of hepatoma in clinical application. J Drug Target. 2010;18(7):557-66.
92. Liu CH, Wu CT, Fang J Y. Characterization and formulation optimization of solid lipid nanoparticles in vitamin K1 delivery. Drug Dev Ind Pharm. 2010;36(7):751-61.
93. Varshosaz J, Minayian M, Moazen E. Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles. J Liposome Res. 2010;20(2):115-23.
94. Hu L, Xing Q, Meng J, Shang C. Preparation and enhanced oral bioavailability of cryptotanshinone-loaded solid lipid nanoparticles. AAPS PharmSciTech. 2010;11(2): 582-7.
95. Singh S, Dobhal AK, Jain A, Pandit JK, Chakraborty S. Formulation and evaluation of solid lipid nano-particles of a water soluble drug: Zidovudine. Chem Pharm Bull. 2010;58 (5):650-5.
96. Bianco MA, Gallarate M, Trotta M, Battaglia L. Amphotericin B loaded SLN prepared with the coac-ervation technique. J Drug Deliv Sci Technol. 2010;20(3):187-91.
97. Ali H, Shirode AB, Sylvester PW, Nazzal S. Preparation, characterization, and anticancer effects of simvastatin-tocotrienol lipid nanoparticles. Int J Pharm. 2010;389 (1-2):223-31.
98. Paliwal R, Rai S, Vaidya B, Khatri K, Goyal AK, Mishra N, Mehta A, Vyas SP. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomed Nanotechnol Biol Med. 2009;5(2):184-91.
99. Xu Z, Chen L, Gu W, Gao Y, Lin L, Zhang Z, Xi Y, Li Y. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials. 2009;30(2):226-32.
100. Al Haj NA, Abdullah R, Ibrahim S, Bustamam A. Tamoxifen drug loading solid lipid nanoparticles prepared by hot high pressure homogenization techniques. Am J Pharmacol Toxicol. 2008;3(3):219-24.
101. Han J, Li Z, Cen Q, Pan YF, Yin LM. Preparation and quality evaluation of paclitaxel loaded solid lipid nanoparticles. Chin Tradit Herb Drugs. 2008;39(7):996-1000.
102. Zhang D, Tan T, Gao L. Preparation of oridonin-loaded solid lipid nanoparticles and studies on them in vitro and in vivo. Nanotechnology. 2006;17(23):5821-8.
103. Zhuang C, Li N, Wang M, Zhang X, Pan W, Peng J, Pan Y, Tang X. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved bioavailability. Int J Pharm. 2010;394:179-85.
104. Li F, Weng Y, Wang L, He H, Yang J, Tang X. The efficacy and safety of bufadienolides: loaded nanostructured lipid carriers. Int J Pharm. 2010;393:203-11.
105. Wissing SA, Lippacher A, Muller RH. Investigations on the occlusive properties of solid lipid nano-particles (SLN). J Cosmetic Sci. 2001;52:313-24.
106. Zhai H, Maibach HI. Effects of skin occlusion on the pecutaneous absorption: an overview. Skin Pharmacol Appl. 2001;14:1-10.
107. Dingler A, Blum RP, Niehus H, Muller RH, Gohla S. Solid lipid nanoparticles (SLN/Lipopearls): a pharmaceutical and cosmetic carrier for the application of vitamin E in dermal products. J Microen-capsul. 1999;16:751-67.
108. de Vringer T, de Ronde HAG. Preparation and structure of a water-in-oil cream containing lipid nano-particles. J Pharm Sci. 1995;84:466-72.
109. Wissing SA, Muller RH. The infuence of the crystallinity of lipid nanoparticles on their occlusive properties. Int J Pharm. 2002;242:377-9.
110. Pathak P, Nagarsenkar M. Formulation and evaluation of lidocaine lipid nanosystems for dermal delivery. AAPS PhamSciTech. 2009;10(3):985-92.
111. Pople VP, Singh KS. Development and evaluation of topical formulation containing solid lipid nano-particles of vitamin A. AAPS PharmSciTech. 2006;7(4):E1-7.
112. Teeranachaideekul V, Boomne P, Souto EB, Muller RH, Junyaprasert VB. Infuence of oil content on physicochemical properties and skin distribution of Nile red loaded NLC. J Control Release. 2008;128:134-41.
113. Pardeike J, Muller RH. Coenzyme Q10-loaded NLCs: preparation, occlusive properties and penetration enhancement. Pharm Technol Eur. 2007 Jul 1.
114. Souto EB, Wissing SA, Barbosa CM, Muller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm. 2006;278:71-7.
115. Kwon TK, Lim KB, Kim JC. Solid lipid nanoparticles coated with silk fbroin. J Ind Eng Chem. 2010; Article in press.
116. Bhalekar MR, Pokharkar V, Madgulkar A, Patil N, Patil N. Preparation and evaluation of miconazole nitrate-loaded solid lipid nanoparticles for topical delivery. AAPS PharmSciTech. 2009;10(1):289-6.
117. Kuchler S, Wolf NB, Heilmann S, Weindl G, Helfmann J, Yahya MM, Stein C, Schafer-Korting M. 3D-Wound healing model: infuence of morphine and solid lipid nanoparticles. J Biotechnol. 2010;148(1):24-30.
118. Perugini P, Tomasi C, Vettor M, Dazio V, Conti B, Genta I, Pavanetto F. Influence of SLN matrix modi-fcation on in vitro and in vivo nanoparticle performances. Int J Pharm Pharm Sci. 2010;2(3):37-42.
119. Moddaresi M, Brown MB, Tamburic S, Jones SA. Tocopheryl acetate disposition in porcine and human skin when administered using lipid nanocarriers. J Pharm Pharmacol. 2010;62(6):762-9.
120. Teskac K, Kristl J. The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int J Pharm. 2010;390(1):61-9.
121. Gaddam N, Aukunuru J. Systemic delivery of diclofenac sodium after topical application of gels incorporated with drug-loaded solid lipid nanoparticles (SLN). J Pharm Res Health Care. 2010;2(2): 177-87.
122. Carlotti ME, Sapino S, Peira E, Gallarate M, Ugazio E. On the photodegradation of dianthrol in different topical formulation: use of SLN to increase stability of the drug. J Dispersion Sci Technol. 2009;30(10):1517-24.
123. Chirio D, Gallarate M, Trotta M, Carlotti ME, Gaudino EC, Cravotto G. Infuence of α- and γ- cyclo-dextrin lipophilic derivatives on curcumin-loaded SLN. J Inclusion Phenom Mol Recognit Chem. 2009;65(3):391-402.
124. Kim ST, Jang DJ, Kim JH, Park JY, Lim JS, Lee SY, Lee KM, Lim SJ, Kim CK. Topical administration of cyclosporin A in a solid lipid nanoparticle formulation. Pharmazie. 2009;64(8):510-14.
125. Lee CM, Jeong HJ, Park JW, Kim J, Lee KY. Temperature-induced release of all-trans-retinoic acid loaded in solid lipid nanoparticles for topical delivery. Macromol Res. 2008;16(8):682-5.
126. Liu W, Hu M, Liu W, Xue C, Xu H, Yang X. Investigation of the carbopol gel of solid lipid nano-particles for the transdermal iontophoretic delivery of triamcinolone acetonide acetate. Int J Pharm. 2008;364(1):135-41.
127. Mandawgade SD, Patravale VB. Development of SLNs from natural lipids: application to topical delivery of tretinoin. Int J Pharm. 2008;363(1-2):132-8.
128. Shah KA, Date AA, Joshi MD, Patravale VB. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int J Pharm. 2007;345(1-2):163-71.
129. Ma Q, Xia Q, Lu Y, Hao X, Gu N, Lin X, Luo D. Preparation of tea polyphenols-loaded solid lipid nanoparticles based on the phase behaviors of hot microemulsions. Diffusion and Defect Data Pt.B: Solid State Phenomena. 2007;121-123(2):705-8.
130. Zhou H, Ma Q, Xia Q, Lu Y, Gu N, Miao X, Luo D. Preparation and cytotoxicity of imiquimod-loaded solid lipid nanoparticles. Diffusion and Defect Data Pt.B: Solid State Phenomena. 2007;121-123(1):271-4.
131. Gonzalez-Mira E, Nikolic S, García ML, Egea MA, Souto EB, Calpena AC. Potential use of nanostruc-tured lipid carriers for topical delivery of furbiprofen. J Pharm Sci. 2011;100(1):242-51.
132. Agrawal Y, Petkar KC, Sawant KK. Development, evaluation and clinical studies of Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis. Int J Pharm. 2010;401(1-2):93-102.
133. Sanad RA, AbdelMalak NS, elBayoomy TS, Badawi AA. Formulation of a novel oxybenzone-loaded nanostructured lipid carriers (NLCs). AAPS PharmSciTech. 2010 Dec;11(4):1684-94.
134. Lin YK, Huang ZR, Zhuo RZ, Fang JY. Combination of calcipotriol and methotrexate in nanostructu-red lipid carriers for topical delivery. Int J Nanomed. 2010;5 (1):117-28.
135. Wang JJ, Liu KS, Sung KC, Tsai CY, Fang JY. Skin permeation of buprenorphine and its ester prodrugs from lipid nanoparticles: lipid emulsion, nanostructured lipid carriers and solid lipid nanoparticles. J Microencapsul. 2009;26(8):734-47.
136. Junyaprasert VB, Teeranachaideekul V, Souto EB, Boonme P, Muller RH. Q10-loaded NLC versus nanoemulsions: Stability, rheology and in vitro skin permeation. Int J Pharm. 2009;377(1-2):207-14.
137. Silva AC, Santos D, Ferreira DC, Souto EB. Minoxidil-loaded nanostructured lipid carriers (NLC): characterization and rheological behaviour of topical formulations. Pharmazie. 2009;64(3):177-82.
138. Joshi M, Patravale V. Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm. 2008;346(1-2):124-32.
139. Teeranachaideekul V, Souto EB, Junyaprasert VB, Muller RH. Cetyl palmitate-based NLC for topical delivery of coenzyme Q10: development, physicochemical characterization and in vitro release studies. Eur J Pharm Biopharm. 2007;67(1):141-8.
140. Gonzalez-Mira E, Egea MA, Garcia ML, Souto EB. Design and ocular tolerance of furbiprofen loaded ultrasound-engineered NLC. Colloids Surf B. 2010;81(2):412-21.
141. Shen J, Deng Y, Jin X, Ping Q, Su Z, Li L. Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: improving in vivo ocular distribution. Int J Pharm. 2010;402(1-2):248-53.
142. Araujo J, Gonzalez-Mira E, Egea MA, Garcia ML, Souto EB. Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications. Int J Pharm. 2010;393(1-2):167-75.
143. Shen J. Sun M, Ping Q, Ying Z, Liu W. Incorporation of liquid lipid in lipid nanoparticles for ocular drug delivery enhancement. Nanotechnology. 2010 Jan 15;21(2):025101. Epub 2009 Dec 3.
144. Li X, Nie SF, Kong J, Li N, Ju CY, Pan WS. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm. 2008;363(1-2): 177-82.
145. Ma QH, Hao XZ, Zhou HF, Tong S, Xia Q, Gu N. Preparation and stability of all-trans retinoic acid loaded nanostructured lipid carriers. Chin Pharm J. 2006;41(16): 1244-9.
146. Muchow M, Maincent P, Muller RH, Keck CM. Production and characterization of testosterone unde-canoate-loaded NLC for oral bioavailability enhancement. Drug Dev Ind Pharm. 2011;37(1):8-14.
147. Nayak AP, Tiyaboonchai W, Patankar S, Madhusudhan B, Souto EB. Curcuminoids-loaded lipid nano-particles: novel approach towards malaria treatment. Colloids Surf B. 2010;81(1):263-73.
148. Jia L, Zhang D, Li Z, Duan C, Wang Y, Feng F, Wang F, Liu Y, Zhang Q. Nanostructured lipid carriers for parenteral delivery of silybin: biodistribution and pharmacokinetic studies. Colloids Surf B. 2010;80(2):213-8.
149. Zhao XL, Yang CR, Yang KL, Li KX, Hu HY, Chen DW. Preparation and characterization of nanostruc-tured lipid carriers loaded traditional Chinese medicine, zedoary turmeric oil. Drug Dev Ind Pharm. 2010;36(7):773-80.
150. Patlolla RR, Chougule M, Patel AR, Jackson T, Tata PNV, Singh M. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Release. 2010;144(2):233-41.
151. Joshi M, Pathak S, Sharma S, Patravale V. Design and in vivo pharmacodynamic evaluation of nanostruc-tured lipid carriers for parenteral delivery of artemether: nanoject. Int J Pharm. 2008;364(1):119-26.
152. Liu K, Sun J, Wang Y, He Y, Gao K, He Z. Preparation and characterization of 10-hydroxycamptothe-cin loaded nanostructured lipid carriers. Drug Dev Ind Pharm. 2008;34 (5):465-71.
153. Doktorovova S, Araujo J, Garcia ML, Rakovsky E, Souto EB. Formulating futicasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC). Colloids Surf B. 2010;75(2):538-42.
154. Luo Q, Zhao J, Zhang X, Pan W. Nanostructured lipid carrier (NLC) coated with chitosan oligosaccha-rides and its potential use in ocular drug delivery system. Int J Pharm. 2011 Jan 17;403(1-2):185-91.
155. Shen J, Wang Y, Ping Q, Xiao Y, Huang X. Mucoadhesive effect of thiolated PEG stearate and its modifed NLC for ocular drug delivery. J Control Release. 2009;137(3): 217-23.
156. Keck CM, Schwabe K. Silver-nanolipid complex for application to atopic dermatitis skin: rheological characterization, in vivo effciency and theory of action. J Biomed Nanotachnol. 2009;5(4):428-36.
157. Ying XY, Du YZ, Chen WW, Yuan H, Hu FQ. Preparation and characterization of modifed lipid nano-particles for doxorubicin controlled release. Pharmazie. 2008;63(12): 878-82.
158. Zhang XG, Miao J, Dai YQ, Du YZ, Yuan H, Hu FQ. Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. Int J Pharm. 2008;361(1-2):239-44.
159. Zhang X, Gan Y, Gan L, Nie S, Pan W. PEGylated nanostructured lipid carriers loaded with 10-hydroxy-camptothecin: an effcient carrier with enhanced anti-tumour effects against lung cancer. J Pharm Pharmacol. 2008;60(8):1077-87.
160. Zhang Z, Sha X, Shen A, Wang Y, Sun Z, Gu Z, Fang X. Polycation nanostructured lipid carrier, a novel nonviral vector constructed with triolein for efficient gene delivery. Biochem Biophy Res Com-mun. 2008;370(3):478-82.
161. Yuan H, Wang LL, Du YZ, You J, Hu FQ, Zeng S. Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsifcation. Colloids Surf B. 2007;60(2): 174-9.
162. Li JC, Sha XY, Zhang LJ, Fang XL. 9-Nitrocamptothecin nanostructured lipid carrier system: in vitro releasing characteristics, uptake by cells, and tissue distribution in vivo. Yaoxue Xuebao. 2005;40(11):970-5.
163. Muller RH, Maaben S, Weyhers H, Specht F, Lucks JH. Cytotoxicity of magnetite-loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. Int J Pharm. 1996;138:85-94.
164. Muller RH, Rahl D, Runge S, Schulze-Forster K, Mehnert W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res. 1997; 14(4):458-62.
165. Scholer N, Hahn H, Muller RH, Liesenfeld O. Effect of lipid matrix and size on solid lipid nanoparti-cles (SLN) on the viability and cytokine production of macrophages. Int J Pharm. 2002;231:167-76.
166. Sandri G, Bonferoni MC, Gokce EH, Ferrari F, Rossi S, Patrini M, Caramella C. Chitosan-associated SLN: in vitro and ex vivo characterization of cyclosporine A loaded ophthalmic systems. J Microen-capsul. 2010;27(8):735-46.
167. Kalam MA, Sultana Y, Ali A, Aqil M, Mishra AK, Chuttani K. Preparation, characterization, and evaluation of gatifoxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system. J Drug Target. 2010;18(3):191-204.
168. Basaran E, Demirel M, Sirmagul B, Yazan Y. Cyclosporine-A incorporated cationic solid lipid nano-particles for ocular delivery. J Microencapsul. 2010;27(1):37-47.
169. Attama AA, Reichl S, Muller-Goymann CC. Sustained release and permeation of timolol from surface-modifed solid lipid nanoparticles through bioengineered human cornea. Curr Eye Res. 2009;34(8):698-705.
170. Gokce EH, Sandri G, Bonferoni MC, Rossi S, Ferrari F, Guneri T, Caramella C. Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity. Int J Pharm. 2008;364(1):76-86.
171. Attama AA, Reichl S, Muller-Goymann CC. Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm. 2008; 355(1-2):307-13.
172. Li YZ, Sun X, Gong T, Liu, J, Zuo J, Zhang ZR. Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles. Pharm Res. 2010;27(9):1977-86.
173. Xie S, Pan B, Wang M, Zhu L, Wang F, Dong Z, Wang X, Zhou W. Formulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil solid lipid nanoparticles. Nanomedi-cine. 2010;5(5):693-701.
174. Nassimi N, Schleh C, Lauenstein HD, Hussein R, Lubbers K, Pohlmann G, Switalla S, Sewald K, Muller M, Krug N, Muller-Goymann CC, Braun A. A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. Eur J Pharm Biopharm. 2010;75(2):107-16.
175. Lu W, He LC, Wang CH, Li YH, Zhang SQ. The use of solid lipid nanoparticles to target a lipophilic molecule to the liver after intravenous administration to mice. Int J Biol Macromol. 2008;43(3):320-4.
176. Chattopadhyay N, Zastre J, Wong HL, Wu XY, Bendayan R. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm Res. 2008;25(10):2262-71.
177. Chen G, Hou SX, Hu P, Hu QH, Guo DD, Xiao Y. In vitro dexamethasone release from nanoparticles and its pharmacokinetics in the inner ear after administration of the drug-loaded nanoparticles via the round window. J South Med Univ. 2008;28(6):1022-4.
178. Liu J, Gong T, Fu H, Wang C, Wang X, Chen Q, Zhang Q, He Q, Zhang Z. Solid lipid nanoparticles for pulmonary delivery of insulin. Int J Pharm. 2008;356(1-2):333-44.
179. Nassimi N, Schleh C, Lauenstein HD, Hussein R, Lubbers K, Pohlmann G, Switalla S, Sewald K, Mul-ler M, Krug N, Muller-Goymann CC, Braun A. Low cytotoxicity of solid lipid nanoparticles in in-vitro and ex vivo lung models. Inhalational Toxicol. 2009; 1:104-9.
180. Jain A, Agarwal A, Majumder S, Lariya N, Khaya A, Agrawal H, Majumdar S, Agrawal GP. Man-nosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Release. 2010;148(3):359-67.
181. Kyo YC, Chen HH. Effect of electromagnetic feld on endocytosis of cationic solid lipid nanoparticles by human brain-microvascular endothelial cells. J Drug Target. 2010;18(6):447-56.
182. Wu L, Tang C, Yin C. Preparation and characterization of paclitaxel delivery system based on semi-solid lipid nanoparticles coated with poly (ethylene glycol). Pharmazie. 2010;65(7):493-9.
183. Wang W, Zhao X, Hu H, Chen D, Gu J, Deng Y, Sun J. Galactosylated solid lipid nanoparticles with cucurbitacin B improves the liver targetability. Drug Deliv. 2010;17 (3):114-22.
184. Teixeira J, Gehm C, Julio A, Castro C, Fonseca J, Martins S, Ferreira D, Sarmento B. Chitosan as mucoadhesive agent to enhance absorption of therapeutic proteins encapsulated into solid lipid nano-particles. Technical Proceedings of the 2009 NSTI Nanotechnology Conference and Expo, NSTI-Nanotech. 2009;2:111-4.
185. Wang SL, Xie SY, Zhu LY, Wang FH, Zhou WZ. Effects of poly (lactic-co-glycolic acid) as a co-emulsifer on the preparation and hypoglycaemic activity of insulin-loaded solid lipid nanoparticles. IET Nanobiotechnol. 2009;3(4):103-8.
186. Yu W, Liu C, Ye J, Zou W, Zhang N, Xu W. Novel cationic SLN containing a synthesized single-tailed lipid as a modifer for gene delivery. Nanotechnology. 2009 May 27;20(21):215102.
187. Pang X, Cui F, Tian J, Chen J, Zhou J, Zhou W. Preparation and characterization of magnetic solid lipid nanoparticles loaded with ibuprofen. Asian J Pharm Sci. 2009;4(2): 132-7.
188. Gao Y, Gu W, Chen L, Xu Z, Li Y. The role of daidzein-loaded sterically stabilized solid lipid nanopar-ticles in therapy for cardio-cerebrovascular diseases. Biomaterials. 2008; 29(30):4129-36.
189. Jain SK, Chaurasiya A, Gupta Y, Jain A, Dagur P, Joshi B, Katoch VM. Development and characterization of 5-FU bearing ferritin appended solid lipid nanoparticles for tumour targeting. J Microencapsul. 2008;25(5):289-97.
190. Wan F, You J, Sun Y, Zhang XG, Cui FD, Du YZ, Yuan H, Hu FQ. Studies on PEG-modifed SLNs loading vinorelbine bitartrate (I): preparation and evaluation in vitro. Int J Pharm. 2008;359(1-2); 104-10.
191. Li X, Lin X, Zheng L, Yu L, Lv F, Zhang Q, Liu W. Effect of poly(ethylene glycol) stearate on the phase behavior of monocaprate/Tween80/water system and characterization of poly(ethylene glycol) stearate-modifed solid lipid nanoparticles. Colloids Surf A. 2010;317(1-3):352-9.
192. Zhang JQ, Liu J, Li XL, Jasti BR. Preparation and characterization of solid lipid nanoparticles containing silibinin. Drug Deliv. 2007;14(6):381-7.
193. Pang XJ, Zhou J, Chen JJ, Yu MH, Cui FD, Zhou WL. Synthesis of ibuprofen loaded magnetic solid lipid nanoparticles. IEEE Trans Magnetics. 2007;43(6):2415-7.
194. Zhang N, Ping Q, Huang G, Xu W, Cheng Y, Han X. Lectin-modifed solid lipid nanoparticles as carriers for oral administration of insulin. Int J Pharm. 2006;327(1-2): 153-9.